StockNews.AI
CERO
StockNews.AI
145 days

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

1. CERo's FDA amendment approval accelerates clinical trial timelines. 2. Initial patient dosing for CER-1236 is set for first half of 2025. 3. CERo's presentation accepted at ASCO conference scheduled for May 30-June 5. 4. CER-1236 aims to treat relapsed/refractory acute myeloid leukemia with innovative methods. 5. Completion of manufacturing processes significantly shortens trial initiation timeline.

8m saved
Insight
Article

FAQ

Why Bullish?

CERo's FDA approval and upcoming ASCO presentation indicate strong progress. Historical cases show FDA approvals often correlate with stock price increases.

How important is it?

Upcoming milestones and FDA approvals are critical to CERO’s progress and investor sentiment. The ASCO conference may attract attention and potential partnerships.

Why Short Term?

Immediate impacts are expected around the clinical trial initiation and ASCO conference. Similar biotech firms have shown short-term increases post-FDA announcements.

Related Companies

AMGNJNJBMYGILD
Company reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN FRANSCISCO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received positive review from the U.S. Food and Drug Administration (FDA) on an amendment to its IND around Chemistry, Manufacturing and Controls (CMC), which marks completion of the Company’s final commitment to FDA prior to initiating patient dosing and shortens the manufacturing timeline by about a week. With this completion, the Company is on track to meet its anticipated timeline of dosing initial subjects during the first half of 2025. Chris Ehrlich, CERo Therapeutics CEO added, “This is a key completion as we ramp up for initiating our clinical trial of CER-1236. Very often there are additional delays prior to initiating a trial, including manufacturing, chemistry and other follow-on information that FDA may request at the time of or following the clearance of an IND. We have worked diligently to ensure continued progress with the FDA, avoiding additional delays. This is due to our fantastic team and top-notch consultants and partners, including UC Davis, our manufacturing partner, that have been working alongside us on this process. In the meantime, we received acceptance from the American Society of Clinical Oncology (ASCO) of an abstract, which we expect to present at the annual conference in Chicago May 30-June 5. We will provide more updates on that presentation, as well as updating on our program development in the near term.” The first-in-human, multi-center, open label, Phase 1/ 1b study is designed to evaluate the safety and preliminary efficacy of CER-1236 in patients with relapsed/refractory measurable residual disease positive acute myeloid leukemia. The two-part study will begin with dose escalation to determine highest tolerated dose and recommended dose for Phase 2, followed by an expansion phase to further evaluate safety and efficacy. Primary outcome measures include incidence of adverse events (AEs) and serious adverse events (SAEs), incidence of dose limited toxicities and estimation of overall response rate (ORR), complete response (CR), composite complete response (cCR), and measurable residual disease (MRD). Secondary outcome measures include pharmacokinetics (PK). About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor (“CAR-T”) cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2025 for hematological malignancies. Forward-Looking Statements This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the product development and manufacturing of CER-1236, financial position, business strategy and the plans and objectives of management for future operations of CERo the timing and completion of the reverse stock split, and the acceptance and implementation of its proposed plan of compliance with Nasdaq continued listing standards. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K, filed on April 2, 2024, and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contact:Chris EhrlichChief Executive Officerchris@cero.bio Investors:CORE IRinvestors@cero.bio

Related News